{
  "docId": "019de073-ceb7-7719-9dd4-8c66dbfaed37",
  "docSlug": "b2317289d3b06d938a683c10bc0d40e0",
  "documentTitle": "Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides",
  "authorId": "organicell-regenerative-medicine",
  "authorName": "Organicell Regenerative Medicine",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 17,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes both stock market data and business financial summary in a side-by-side table format.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ceb7-7719-9dd4-8c66dbfaed37/3",
  "deckHref": "/decks/019de073-ceb7-7719-9dd4-8c66dbfaed37",
  "deckJsonHref": "/decks/019de073-ceb7-7719-9dd4-8c66dbfaed37.json",
  "deckAnchorHref": "/decks/019de073-ceb7-7719-9dd4-8c66dbfaed37#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.42,
        "w": 0.42,
        "x": 0.54,
        "y": 0.12
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5263a6d-73b5-4a81-a52b-c9c020a64b13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "Company was recapitalized and appointed new management in August of 2022. Company is generating revenue and approved for Phase I/II clinical trials for COVID Long Hauler, COPD, and Osteoarthritis.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62a03ea2-0aa6-4e7f-8795-74d695afaf4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Organicell Regenerative Medicine, Inc. (OCEL) Organicell is a publicly-traded (OTCQB), clinical stage biopharmaceutical company that is committed to the research, development, and manufacture of new technologies in biologic medicine and therapeutics.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b3dccdd-6497-4ad5-b775-d7c66c80bef1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.04,
        "y": 0.49
      },
      "kind": "table",
      "text": "Stock Information as of September 2022*: Stock Price $0.04, Shares Outstanding 1.476B, Warrants Outstanding 428MM, Market Cap $62MM, Average Volume 706,772, 52 Week Range $0.01 - $0.11",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03c6c476-8d76-4344-830a-982d844c6fb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.49
      },
      "kind": "table",
      "text": "Business Summary as of September 2022*: August 22 Revenues $480,000, Cash on Hand $4.12MM, Revenue FY 2020 to FYE 2022 YTD $14.4MM, Revenue in FY 2021 $5.6MM, Revenue YTD FY 2022 $5.8MM, Funds Raised since Aug 2022 $6.6MM",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4475eb3f-5931-4cd6-b411-8eacf3555f35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Organicell Snapshot",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa0837c1-a160-4632-a3b6-cd8059aac291",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "88318d4c-18c5-4e20-b77f-af06b475b2c0",
      "evidence": "Organicell Regenerative Medicine, Inc. (OCEL) Organicell is a publicly-traded (OTCQB), clinical stage biopharmaceutical company",
      "confidence": 0.9
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "92853cd2-ac9e-4a08-a464-7c2c3eaf1559",
      "evidence": "Business Summary as of September 2022*: August 22 Revenues $480,000, Cash on Hand $4.12MM",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 4,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "89ac54cf-2ebf-47cf-afab-3bd5b2bbb6bf",
      "evidence": "The Key Investment Considerations and Organicell Snapshot slides imply the importance of investing in Organicell",
      "position": 0,
      "objective": "What are the consequences of not investing in Organicell?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}